DMA Diamedica Therapeutics

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


DiaMedica Inc. (TSX VENTURE:DMA), announced today that it has filed a final
short form prospectus, dated March 14, 2013 relating to its previously announced
offering (the "Offering") of units of the Company (the "Units"). The Company
will offer 4,444,500 Units at a price of $0.90 per Unit for gross proceeds to
the Company of $4,000,050. The Offering is being placed on a commercially
reasonable efforts agency basis by Sora Group Wealth Advisors Inc. (the
"Agent"). The Company has granted to the Agent an option exercisable in whole or
in part at any time within 30 days of the closing date of the Offering, to
increase the number of Units offered by up to 15% on the same terms and
conditions.


DiaMedica intends to use the net proceeds from the offering for research and
development, including a Phase I/II clinical trial, our manufacturing activities
in support of such research and development and for working capital and general
and administrative purposes as described in the prospectus.


Each Unit will consist of one common share in the capital stock of DiaMedica (a
"Common Share") and one half of one common share purchase warrant (each whole
warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase
one additional Common Share for the price of $1.10 within three years from the
closing date of the Offering, subject to an acceleration of the expiry date of
such Warrants in certain circumstances as more particularly described in the
Prospectus.


The Company has received the conditional approval of the TSX Venture Exchange
(the "Exchange") for the listing of Common Shares forming part of the Offering.
Listing is subject to DiaMedica satisfying all requirements of the Exchange.


The closing of the Offering is anticipated to take place on or about March 22,
2013, or such other date as the Agent and DiaMedica may determine.


About DiaMedica

DiaMedica Inc. (TSX VENTURE:DMA) is a biotechnology company developing
first-in-class treatments for the treatment of diabetes. DiaMedica's lead
compound, DM-199, is a recombinant human protein for the treatment of both Type
1 and Type 2 diabetes and their complications. The Company is also developing
the first therapeutic GPCR agonist monoclonal antibody, DM-204, for the
treatment of Type 2 diabetes and cardiovascular disease. DiaMedica's shares
trade on the Toronto Stock Exchange Venture (TSX VENTURE:DMA). For more
information please visit www.diamedica.com.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
President and CEO
763-710-4455
info@diamedica.com
www.diamedica.com

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024